AGEN

Agenus Inc.

Price

chg

quotes and stock data delayed 15 minutes

Cash

$79.2M

Burn Rate (Qtr)

$47.5M

Mkt Cap

mkt cap api

52 wk hi

52 wk low

low api

high api

*cash/burn updated:

Q3 '20

Company Profile

The company’s I-O portfolio is comprised of checkpoint antibodies, cell therapies, vaccines, and adjuvants, representing a combination of synergistic agents to deliver curative patient outcomes

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Balstilimab (AGEN2034)

Recurrent/Metastatic Cervical Cancer

BLA Submission (Ph2 data)

H1 2021

Balstilimab (anti- PD-1) + Zalifrelimab (anti-CTLA-4)

Refractory Cervical Cancer

BLA filing

H1 2021

AGEN1181 (anti-CLTA-4)

Advanced endometrial cancer

Phase 2 (Data)

AGEN-797 (Unmodified allogenic iNTKs)

Cancer

Phase 1

January 2021 (Est)

Initiation

Dec '20 Co. presentation: "Phase 1: Anticipated 2020"

Allogenic iNKTs

COVID-19

Phase 1 Trial

TBD

Update

AGEN 1777 (anti-TIGIT)

Cancer

IND Submission

AGEN1327 (anti-TIGIT)

Cancer

IND Submission

Q1 2021

Submission

Dec 2020 corp slide deck - IND Q1 2021.

AGEN

Agenus Inc.

Price

chg

Company Profile

Drug Pipeline

Recent Posts